A detailed history of Victory Capital Management Inc transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 343,344 shares of CRNX stock, worth $19 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
343,344
Previous 226,687 51.46%
Holding current value
$19 Million
Previous $10.2 Million 72.74%
% of portfolio
0.02%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$43.83 - $54.98 $5.11 Million - $6.41 Million
116,657 Added 51.46%
343,344 $17.5 Million
Q2 2024

Aug 05, 2024

SELL
$42.12 - $51.91 $1.28 Million - $1.58 Million
-30,458 Reduced 11.84%
226,687 $10.2 Million
Q1 2024

May 03, 2024

BUY
$34.76 - $46.81 $2.54 Million - $3.42 Million
73,038 Added 39.67%
257,145 $12 Million
Q4 2023

Feb 05, 2024

BUY
$25.62 - $37.07 $3.56 Million - $5.16 Million
139,117 Added 309.22%
184,107 $6.55 Million
Q3 2023

Nov 06, 2023

BUY
$15.97 - $30.59 $718,490 - $1.38 Million
44,990 New
44,990 $1.34 Million
Q4 2022

Feb 09, 2023

SELL
$15.49 - $19.05 $505,593 - $621,792
-32,640 Reduced 32.95%
66,428 $1.22 Million
Q3 2022

Nov 02, 2022

SELL
$18.11 - $22.37 $203,013 - $250,767
-11,210 Reduced 10.17%
99,068 $1.95 Million
Q1 2022

May 04, 2022

SELL
$17.15 - $28.31 $77,003 - $127,111
-4,490 Reduced 3.91%
110,278 $2.42 Million
Q4 2021

Feb 07, 2022

SELL
$19.35 - $28.41 $1.56 Million - $2.29 Million
-80,670 Reduced 41.28%
114,768 $3.26 Million
Q3 2021

Nov 02, 2021

BUY
$16.88 - $25.23 $1.96 Million - $2.92 Million
115,820 Added 145.47%
195,438 $4.11 Million
Q2 2021

Aug 03, 2021

SELL
$15.9 - $21.15 $56,286 - $74,871
-3,540 Reduced 4.26%
79,618 $1.5 Million
Q1 2021

May 04, 2021

BUY
$13.3 - $17.55 $408,576 - $539,136
30,720 Added 58.58%
83,158 $1.27 Million
Q4 2020

Feb 01, 2021

SELL
$12.08 - $17.46 $111,619 - $161,330
-9,240 Reduced 14.98%
52,438 $740,000
Q3 2020

Nov 09, 2020

SELL
$13.62 - $17.66 $28,329 - $36,732
-2,080 Reduced 3.26%
61,678 $966,000
Q2 2020

Aug 07, 2020

SELL
$13.04 - $23.23 $1.58 Million - $2.81 Million
-120,966 Reduced 65.48%
63,758 $1.12 Million
Q1 2020

May 04, 2020

SELL
$11.52 - $26.46 $121,121 - $278,200
-10,514 Reduced 5.39%
184,724 $2.72 Million
Q4 2019

Feb 06, 2020

BUY
$15.24 - $25.09 $70,667 - $116,342
4,637 Added 2.43%
195,238 $4.9 Million
Q4 2019

Feb 04, 2020

SELL
$15.24 - $25.09 $362,209 - $596,314
-23,767 Reduced 11.09%
190,601 $4.09 Million
Q3 2019

Nov 12, 2019

BUY
$14.91 - $25.01 $2.16 Million - $3.62 Million
144,698 Added 207.69%
214,368 $3.22 Million
Q2 2019

Aug 15, 2019

BUY
$21.48 - $27.71 $350,124 - $451,673
16,300 Added 30.54%
69,670 $1.74 Million
Q1 2019

May 03, 2019

SELL
$21.07 - $29.31 $12,431 - $17,292
-590 Reduced 1.09%
53,370 $1.22 Million
Q4 2018

Feb 05, 2019

SELL
$22.4 - $35.39 $915,040 - $1.45 Million
-40,850 Reduced 43.09%
53,960 $1.62 Million
Q3 2018

Nov 01, 2018

BUY
$22.66 - $36.8 $2.15 Million - $3.49 Million
94,810 New
94,810 $2.72 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.98B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.